.png)
.png)
Our double-humanized serum albumin/neonatal Fc receptor mouse model (HSA/hFcRn) maintains an autologous receptor-ligand interaction and can mimic the physiological drug clearance in humans.
This upgraded, immunocompromised Rag1-/- system (HSA/hFcRn-Rag1-/-) allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.
Applications
- Efficacy assessment of drug conjugates, antibodies (e.g., T-cell engagers), and any albumin- and FcRn-binding compounds
- Accurate and predictive PK/PD studies of albumin- and FcRn-binding compounds
HSA/hFcRn-Rag1-/- model features
- Murine Rag1 is invalidated, leading to a deficiency in T- and B-celldevelopment
- Physiological HSA and hFcRn expression profile and regulation in a mouse system, as they are both controlled by their respective endogenous mouse promoters (murine albumin and FcRn expression is abolished)
- Efficient tumor growth upon human cancer cells injection
Clients
No items found.
